Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

IO, Sage-N Launch IDA

By Drug Discovery Trends Editor | November 8, 2012

IO Informatics, the leader in semantic data integration and knowledge management for life sciences and healthcare, announced it has launched its Sentient iDA in cooperation with Sage-N Research, Inc., the inventor of Integrated Data Appliance (iDA) systems.

As the result of a partnership announced March 2012, a new line of iDA products and services will be released, forming plug-and-play, end-to-end solutions for researchers to integrate, discover, and visualize experimental data and information from public resources.

The new Sentient product provides data resources and analytical tools that are pre-loaded onto the Sage-N Research iDA. This collaboration will provide an intuitive interface to enrich internal data with semantically integrated public reference resources, including UniProt, Diseasome, Drugbank, SIDER, and STITCH.

Sage-N Research will leverage their plug-and-play expertise to ensure researchers will be up and running straight out of the box. Additionally, the new product offering will provide 100% of the maintenance and offers server class reliability.

IO Informatics’ knowledge application will allow researchers to load, enrich, and examine their data, and then quickly interrogate it, using an easily extended set of public reference resources. The pairing of the Sage-N Research integration solutions and IO Informatics’ integration and analysis capabilities will offer researchers an unprecedented solution for the discovery, analysis, and visualization of public resources and experimental data.

Robert Stanley, President and CEO of IO Informatics reported, “IO’s Sentient Integrated Data Appliance (iDA) product is a powerful tool for the life-science research community. We are pleased to partner with Sage-N Research to provide plug-and-play capabilities and content to ease the IT burden and lower the barrier to entry for utilizing important reference resources.”

David Chiang, CEO of Sage-N Research, commented, “Our iDAs are known for their integration, reliability and ease of use. We are delighted to be able to work with IO Informatics to help researchers work with unrelated, disparate data and information and turn it into real, actionable, knowledge.”

Date: November 8, 2012
Source: IO Informatics


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE